Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBITDA: 2013-2018

Historic EBITDA for Astria Therapeutics (ATXS) over the last 6 years, with Dec 2018 value amounting to -$26.4 million.

  • Astria Therapeutics' EBITDA fell 10.75% to -$6.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was -$26.4 million, marking a year-over-year increase of 2.79%. This contributed to the annual value of -$26.4 million for FY2018, which is 2.67% up from last year.
  • Latest data reveals that Astria Therapeutics reported EBITDA of -$26.4 million as of FY2018, which was up 2.67% from -$27.1 million recorded in FY2017.
  • Over the past 5 years, Astria Therapeutics' EBITDA peaked at -$21.7 million during FY2014, and registered a low of -$35.6 million during FY2016.
  • For the 3-year period, Astria Therapeutics' EBITDA averaged around -$29.7 million, with its median value being -$27.1 million (2017).
  • Per our database at Business Quant, Astria Therapeutics' EBITDA tumbled by 46.02% in 2015 and then grew by 23.80% in 2017.
  • Yearly analysis of 5 years shows Astria Therapeutics' EBITDA stood at -$21.7 million in 2014, then crashed by 46.02% to -$31.7 million in 2015, then dropped by 12.32% to -$35.6 million in 2016, then grew by 23.80% to -$27.1 million in 2017, then increased by 2.67% to -$26.4 million in 2018.